Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RUCAPARIB vs RUXOLITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RUCAPARIB vs RUXOLITINIB: Safety Overview

Metric RUCAPARIB RUXOLITINIB
Total FAERS Reports 434 68,133
Deaths Reported 50 10,908
Death Rate 11.5% 16.0%
Hospitalizations 310 14,461
Average Patient Age 64.3 yrs 59.7 yrs
% Female Patients 69.5% 48.8%
FDA Approval Date N/A Nov 16, 2011
Manufacturer N/A Incyte Corporation
Route N/A TOPICAL
Marketing Status N/A Prescription